Skip to Content

Pneumococcal 7-Valent Vaccine Dosage

Applies to the following strengths: pediatric

Usual Pediatric Dose for Pneumococcal Disease Prophylaxis

Conjugate Vaccine (PCV 7): The vaccine can be administered to children at least 6 weeks old. However, vaccination typically begins at 2 months of age.

2 months to 6 months: 0.5 mL IM given every 8 weeks for 3 doses followed by a fourth dose at 12 to 15 months.

7 months to 12 months: 0.5 mL IM at least 4 weeks apart for 2 doses followed by a third dose after 1 year of age separated from the second dose by 8 weeks.
Patients that previously received 1 or 2 doses of conjugate vaccine but have not finished the course should receive 0.5 mL IM followed by another dose at least 8 weeks later at 12 to 15 months of age.

1 year to 2 years: 0.5 mL IM at least 8 weeks apart.
Patients that previously received 1 dose before 12 months of age but have not completed the vaccination schedule should receive 0.5 mL followed by a second dose at least 8 weeks later. Patients that have previously received 2 doses prior to 12 months of age should receive 0.5 mL at least 8 weeks after the most recent dose.

2 years to 5 years: 0.5 mL as a single dose. Any patient that had previously started the vaccination and lapsed should receive 0.5 mL as a single dose. Patients with chronic diseases or immunosuppressive conditions should receive two 0.5 mL doses at least 8 weeks apart.

Children with sickle cell, asplenia, HIV infection, immunocompromised, or chronic illness:
0.5 mL IM in two doses at least 8 weeks apart.

Polysaccharide Vaccine:
2 years: 0.5 mL IM or subcutaneously.
Previously vaccinated with pneumococcal conjugate vaccine:
Immunocompromised patients, patients with sickle cell anemia, aplasia, or HIV:
0.5 mL IM or subcutaneously. Revaccination should be given after more than 5 years. Revaccination should not be given after less than 3 years.

Patients with chronic illness: 0.5 mL IM or subcutaneously. Revaccination is not recommended.

Following bone marrow transplant: 0.5 mL IM or subcutaneously at 12 and 24 months following transplantation.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Dialysis

Data not available

Other Comments

As of March 10, 2010, the Advisory Committee on Immunization Practices (ACIP) recommended that pneumococcal 13 valent conjugate vaccine ( Prevnar 13) replace all doses of pneumococcal 7 valent conjugate vaccine (PCV 7; Prevnar). The manufacturer, Wyeth Pharmaceuticals, intends to phase out the previous Prevnar product.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

More about pneumococcal 7-valent vaccine

Consumer resources

Other brands: Prevnar

Professional resources

Related treatment guides

Hide